Clinical Trial

Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML

Study acronym: GMCAII
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to estimate the rate (probability) of complete remission or complete remission with incomplete count recovery (CR/CRi) with negative MRD after induction I and II, event-free survival (EFS), and cumulative incidence (probability) of relapse (CIR), in patients receiving molecular/precision medicine and MRD-driven remission inductions, and to assess secondarily if there is an improvement over the AML2018 protocol.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2024-01-15; most recent amendment 2024-08-21.
Status change: Not Yet Recruiting → Recruiting 2024-02-05
Trial Details
NCT Number NCT06221683
Lead Sponsor Children's Hospital of Soochow University
Conditions AML, Childhood, Acute Myeloid Leukemia
Enrollment 500 participants
Start Date 2024-01-01
Primary Completion 2028-12 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2024-08-22